Reports Q3 revenue $1.17M, consensus $1.14M. “The third quarter and recent weeks have been a transformational period for Lucid, including two key milestones announced last week,” said Lishan Aklog, M.D., Lucid’s Chairman and CEO. “We are now fully armed with a complete body of outstanding clinical data to go along with a renewed commercial focus on programs designed to drive near-term revenue. Our team is ready to make our final push towards broad reimbursement, including our upcoming submission formally seeking Medicare coverage of EsoGuard. We are energized by the vast clinical and market opportunity before us as we seek to expand patient access to our groundbreaking technologies to detect esophageal precancer, and drive shareholder value.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics Announces Convertible Notes Exchange Initiative
- LUCD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Lucid Diagnostics granted patent underlying its EsoGuard Esophageal DNA Ttest
- Castle Biosciences price target raised to $40 from $35 at BTIG
- Lucid Diagnostics management to meet virtually with BTIG